Published in Healthcare Mergers, Acquisitions and Ventures Week, July 31st, 2004
The trial is an open-label multi-center, dose escalation study designed to examine the safety, tolerability, and pharmacokinetics of SNS-595 in order to establish optimal dosing regimens for use in Phase II clinical testing. The drug is a first-in-class cell cycle modulator that kills proliferating cancer cells by inducing apoptosis, or programmed cell death.
Patients with advanced malignancies are being enrolled at four centers in the U.S. In the first trial, SNS-595 will be administered as a single...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.